Head & Neck
Recurrent or second-primary HNSCC within a prior RT field has few options; this consensus standardizes when and how to reirradiate.
ReCOG/ESTRO/ASTRO Reirradiation Consensus
TL;DRInternational expert consensus on definitive and postoperative reirradiation for recurrent HNSCC within previously irradiated fields; ratified by a 17-member rad-onc panel.
Why it mattersRadiation oncology
The additive value is a shared framework where evidence sits mostly at level 3-4: it formalizes patient selection, cumulative-dose accounting across the prior course, and target delineation. Salvage surgery stays first-line where feasible, definitive or postoperative reRT otherwise. It standardizes how you plan and consent a reirradiation candidate, not whether reRT works.
vs leading data
- 15-50% of HNSCC pts recur or develop a second primary; few options within a prior RT field
8 details 2 trials watching
Methods
- 🔍 Core drafting group: 6 radiation oncologists, 3 physicists, 1 research fellow
- 🔍 Ratified by a 17-member international rad-onc panel; single formal vote, no-opinion kept in denominator, no re-vote
- 🔍 Six domains of guidance
- Patient selection
- Imaging
- Target delineation
- Treatment planning
- Dose accumulation across prior + reRT
- Toxicity management
- 🔍 Modern conformal techniques cited: IMRT, VMAT, proton therapy, SBRT (therapeutic ratio improved over past 20 yrs)
Results
- 📐 Consensus thresholds per statement
- High ≥85%
- Moderate 70-84%
- Low <70%
- 📐 Oxford CEBM evidence level tagged per statement
- L1 randomised
- L2 non-randomised prospective / single-arm
- L3 retrospective observational
- L4 expert consensus / extrapolation
Critique
- ⚠️ Excludes nasopharyngeal carcinoma (2021 international recs) and rare histologies
- ⚠️ Evidence mostly low-level and heterogeneous; role of modern reirradiation 'remains undefined'
Open questions
- Prospective randomised trials of modern reirradiation efficacy active SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma Phase 2n=86 · primary completion 2027-07 · phase 2 SBRT +/- pembro reirradiation, PFS EPrecruiting Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC Phase 3n=214 · primary completion 2032-12 · phase 3 RCT: reRCT+pembro vs immunochemo, OS EP
- Optimal cumulative dose constraints across reirradiation courses
- Patient selection criteria predicting reirradiation benefit
📚 Sources · 📄 1 paper
Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology